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Summary. The prevalence of Escherichia coli and Klebsiella pneumoniae that
produce extended-spectrum β-lactamases (ESBL) was investigated in patients of a
university hospital in Split, Croatia. Patients were grouped according to age (pedi-
atric vs. adult), antibiotic type, and hospital ward. From Jan. 2001 to Dec. 2002,
the susceptibility of E. coli and K. pneumoniae isolates to antimicrobials was test-
ed. ESBL production was assayed using the double-disk synergy test. ESBL-pro-
ducing E. coli and K. pneumoniae were detected in all sites of infection sampled.
The percentages of ESBL-positive isolates were higher in the pediatric wards than
in the adult wards. The antibiotics most commonly prescribed to patients in all hos-
pital wards belonged to the third-generation cephalosporin group. Among ESBL
producers, E. coli isolates were more resistant to aminoglycosides, but less resist-
ant to ciprofloxacin and cotrimoxazole. Resistance of E. coli and K. pneumoniae to
ciprofloxacin was exclusively found in isolates from adult patients. None of the
isolates, regardless of ESBL production, was resistant to carbapenemes. In addi-
tion, the prevalence and antimicrobial resistance of ESBL-producing E. coli and K.
pneumoniae isolates differed between pediatric and adult patients. [Int Microbiol
2005; 8(2):119-124]
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Introduction
Many gram-negative bacilli produce extended-spectrum
β-lactamases (ESBL), which are enzymes that mediate resist-
ance to all β-lactams except cephamycins and carbapenems
[6,8,21,14]. ESBL-producing bacteria were first isolated in
Germany in 1983 [20], but they have since been reported
worldwide [6,29]. Most ESBL producers are Escherichia coli
and Klebsiella spp. Infections due to these organisms often
occur in outbreaks, and ESBL have therefore become a serious
problem in hospitalized patients [5,11,18]. Moreover, since
ESBL-producing organisms are frequently also resistant to
aminoglycosides, trimethoprim-sulfamethoxazole (cotrimox-
azole), and quinolones, the therapeutic choices are limited
[6,22,26].
In northern Croatia, the first ESBL-producing Klebsiella
pneumoniae isolates were reported in hospitals in the capital
city, Zagreb, in 1994 [3]. However, there are no published
reports concerning the prevalence and resistance of ESBL-
producing Enterobacteriaceae in southern Croatia. Since
E. coli and K. pneumoniae are the most common producers
Marija Tonkic 1,2*
Ivana Goic Barisic 1
Volga Punda-Polic 1,2
1Department of Clinical
Microbiology, Split University
Hospital, Split, Croatia
2School of Medicine, University 
of Split, Croatia 
INTERNATIONAL MICROBIOLOGY (2005) 8:119-124 
www.im.microbios.org
Received 17 March 2005
Accepted 19 April 2005
*Corresponding author:
M. Tonkic
Department of Clinical Microbiology
Split University Hospital 
Spinciceva 1 
21 000 Split, Croatia
Tel.: +385-21556201. Fax: +385-21389563
E-mail: marija.tonkic@st.htnet.hr
120 INT. MICROBIOL. Vol. 8, 2005
of ESBL, we carried out a survey of ESBL-producing clini-
cal isolates of those bacteria in the only hospital in the largest
county in southern Croatia. The main objective of the survey
was to determine the prevalence of ESBL-producing E. coli
and K. pneumoniae strains isolated as causative agents of
infection in patients treated at Split University Hospital over
a 2-year period. In addition, the number of ESBL-producing
isolates co-resistant to aminoglycosides, cotrimoxazole, and
quinolones was determined. Differences in the antimicrobial
resistance of ESBL-producing isolates obtained from pedi-
atric and adult patients and from the various hospital wards
were analyzed.
Materials and methods
Study design and patients. The study was carried out prospectively
from January 1, 2001 to December 31, 2002 at Split University Hospital
(SUH), Split, Croatia. SUH is a 1651-bed university teaching hospital and
the only hospital in the region. It serves a pediatric and adult population of
about 500,000 and acts as a referral hospital for a wider area of southern
Croatia, thus covering a population of about one million. For each SUH
patient sample, personal data (patient’s name, age), type of specimen, and the
hospital ward to which the patient had been assigned were obtained. In 2001
and 2002, 50,108 and 50,572 patients, respectively, were admitted to the SUH.
Bacterial isolates. The clinical specimens obtained from inpatients of
the SUH yielded 6169 clinical isolates of Enterobacteriaceae. Isolates were
identified at the species level using standard biochemical tests and microbi-
ological methods. Only one isolate per patient was included in the study.
Antimicrobial susceptibility testing. Disk-diffusion tests were
carried out with antibiotic-containing disks (BioRad) on Mueller-Hinton
agar plate (BioRad). The results were expressed as susceptible or resistant
according to the criteria recommended by the National Committee for
Clinical Laboratory Standards (NCCLS) [23]. The following antimicrobial
agents were tested: amikacin (30 µg), amoxicillin/clavulanic acid (20/10 µg),
ampicillin (10 µg), cefepime (30 µg), cefotaxime (30 µg), ceftazidime (30 µg),
ceftriaxone (30 µg), ciprofloxacin (5 µg), cotrimoxazole (1.25/23.75 µg), gen-
tamicin (10 µg), imipenem (10 µg), and meropenem (10 µg).
Detection of ESBL production. ESBL production was detected
using the double-disk synergy (DDS) test [15]. ESBL presence was assayed
using the following antibiotic disks (Becton, Dickinson): cefotaxime (30
µg), cefotaxime/clavulanic acid (30/10 µg), ceftazidime (30 µg), and cef-
tazidime/clavulanic acid (30/10 µg). Klebsiella pneumoniae ATCC 700603
and Escherichia coli ATCC 25922 and ATCC 35218 strains served as posi-
tive controls. For all ESBL-producing isolates of E. coli and K. pneumoniae,
the susceptibility test was reported as resistant to all penicillins,
cephalosporins, and aztreonam, irrespective of the individual in vitro test
result, as recommended by the NCCLS [24].
Antibiotic consumption. Data on the consumption of the most fre-
quently prescribed antibiotics during the year preceding and during the 2-year
study period were obtained from hospital pharmacy records and expressed
as defined daily doses (DDD) per 1000 patients per day. 
Statistical methods. Differences between proportions were analyzed
using the χ2 test. All differences in which the probability of the null hypoth-
esis was p < 0.05 were considered significant.
Results
During the 2-year study period, 6169 consecutive clinical iso-
lates of Enterobacteriaceae were isolated. Of these, 3730
(60.5%) were identified as E. coli and 715 (11.6%) as K. pneu-
moniae. All isolates of E. coli and K. pneumoniae were exam-
ined for ESBL production. Of the 3730 E. coli isolates, 176
(4.7%) were positive for ESBL, while for K. pneumoniae 263
of the 715 isolates (36.8%) were ESBL producers. During the
entire study period, the prevalence of ESBL-producing K.
pneumoniae was significantly higher than that of ESBL-pro-
ducing E. coli (p < 0.001). There was no significant yearly
increase in the prevalence of ESBL-producing E. coli or ESBL-
producing K. pneumoniae during the 2 years studied (p > 0.05).
The sources of the ESBL-producing E. coli and K. pneu-
moniae isolates tested are shown in Table 1. Respiratory tract
infections were the most abundant source of ESBL-produc-
ing E. coli strains (28.7%; p < 0.001), while nearly half of the
ESBL-producing K. pneumoniae strains were isolated from
urinary-tract infections (47.1%; p < 0.001). 
The prevalence of ESBL-producing isolates differed
between hospital wards and between pediatric and adult
patients (Table 2). The prevalence of ESBL-positive E. coli
and K. pneumoniae was highest in isolates obtained from
pediatric wards, and differed significantly from the preva-
lence in neonatal ICU patients. The prevalence of ESBL-pos-
itive E. coli isolates obtained from adult ICU patients was
significantly higher than that in adult patients on other wards
(Table 2). By contrast, only one isolate for each of the two
bacterial species was cultured from samples taken from neu-
rology-ward patients. 
ESBL-positive E. coli isolates were more resistant to some
aminoglycoside compounds, including amikacin (83.9%) and
gentamicin (90.9%), than were ESBL-negative isolates (6.2
and 5.0%, respectively). Although the percentage of ESBL-
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Table 1. Distribution according to clinical sources of Escherichia coli and
Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases
(ESBL)
Number of ESBL-producing isolates
E. coli K. pneumoniae
Source Tested Positive (%) Tested Positive (%)  
Urinary tract 2879 131 (4.5) 350 165 (47.1)
Respiratory tract 94 27 (28.7) 126 25 (19.8)
Skin, soft tissue 119 8 (6.7) 64 28 (43.8)
Blood 86 4 (4.7) 29 10 (34.5)
Othera 552 6 (1.1) 146 35 (24)
Total 3730 176 (4.7) 715 263 (36.8)
a Abdominal specimens, pus, cerebrospinal fluid, etc.
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positive E. coli isolates resistant to ciprofloxacin (1.1%) was
fourfold lower than that of ESBL-negative isolates (4.4%),
the difference was not significant (p = 0.07). In 2001, there
were no ESBL-positive E. coli isolates resistant to cipro-
floxacin, whereas in 2002 two isolates (from the urine of neu-
rosurgery patients) were ciprofloxacin-resistant (resistance in
2002 = 2.3%). ESBL-negative E. coli strains were more
resistant than ESBL-positive E. coli isolates to cotrimoxazole
(19.4% vs. 7.1%, p < 0.0001). None of the E. coli isolates
were resistant to carbapenems. 
ESBL-positive K. pneumoniae isolates were more frequently
resistant to amikacin (58.2%), gentamicin (78.4%), cipro-
floxacin (10.6%), and cotrimoxazole (32.1%) than were ESBL-
negative isolates (6.6%, 8.7%, 4.6% and 13.3%, respectively).
During the 2 years of the study, neither K. pneumoniae nor
E. coli strains resistant to ciprofloxacin were isolated from
specimens obtained from neonates or pediatric patients, and
only two ciprofloxacin-resistant ESBL-positive E. coli isolates
were obtained from adult patients (in the neurosurgery ward).
However, ciprofloxacin-resistant ESBL-positive K. pneumoni-
ae were isolated from adult patients (17.6%). Cotrimoxazole
resistance was lower among ESBL-positive E. coli isolates
obtained from neonates [47/1 (2.1%)] and pediatric patients
[66/2 (3.0%) than among isolates from adult patients (57/9
[15.8%]). Of the ESBL-positive K. pneumoniae isolates
resistant to cotrimoxazole, 18.1% were from neonates, 7.8%
from pediatric patients, and 45.3% from adult patients. 
Antimicrobial resistance between ESBL-negative and
ESBL-positive E. coli and K. pneumoniae isolates is com-
pared in Table 3. ESBL-negative K. pneumoniae isolates
were more resistant to gentamicin, whereas ESBL-negative
E. coli strains were more resistant to cotrimoxazole. Among
ESBL-producers, E. coli isolates were more resistant to
amikacin and gentamicin, whereas K. pneumoniae isolates
were more resistant to ciprofloxacin and cotrimoxazole.
The most frequently prescribed antibiotics, independent
of the year or hospital ward, were third-generation
cephalosporins. From 2000 to 2002, their consumption
increased from 88 to 157 DDD/1000 patients per day in the
pediatric ward, from 4.6 to 12.2 DDD/1000 patients per day,
in the neonatology ward, and from 12.0 to 19.0 DDD/1000
patients per day in the neurology department, which, as noted
above, had the lowest prevalence of ESBL-producing iso-
lates. Regarding aminoglycosides, the consumption of
amikacin by all SUH patients increased from 0.4 to 2.0
DDD/1000 patients per day from 2000 to 2002. By contrast,
gentamicin consumption decreased (from 19 to 7 DDD/1000
patients per day). During the same period, there was no con-
sumption of ciprofloxacin or cotrimoxazole by neonatal
patients, and ciprofloxacin was not prescribed for pediatric
patients. In the neurology department, the ciprofloxacin pre-
scription rate was 0.03 DDD/1000 patients per day. Cotri-
moxazole consumption by patients in the pediatric ward, neu-
rology ward, and adult ICU decreased from 76.0, 103.0, and
134.0 DDD/1000 patients per day to 52.0, 78.0, and 127.0
DDD/1000 patients per day, respectively, from 2000 to 2002.
Discussion
The prevalence of ESBL-producing Enterobacteriaceae in
nosocomial outbreaks of infection has been studied in several
countries [18,25,28,32,33,34,38], as well as in multicenter and
multinational studies [2,4,17,37]. To our knowledge, the pres-
ent study is the first survey in southern Croatia focusing on the
distribution of ESBL-producing E. coli and K. pneumoniae.
The overall prevalence of ESBL-producing E. coli and
K. pneumoniae isolates (439/4445, 9.9%) was higher in the
SUH in southern Croatia than in hospitals in the Netherlands
[34], Italy [33], and Japan [38], but lower than in hospitals in
France [1] and Hong Kong [13]. Although, in our study, E. coli
was more frequently isolated than K. pneumoniae, ESBL pro-
duction was more prevalent in K. pneumoniae, which agrees
with findings reported in previous studies [10,17,32,33,37].
The prevalence of ESBL-positive K. pneumoniae (36.8%) iso-
lates at the SUH was comparable to those in France [7], China
[39], and Lebanon [9]. In the 1994 study carried out in Zagreb,
in northern Croatia, the prevalence of ESBL-producing K.
pneumoniae was 19% [3]. In 2000, however, more than 30%
of Klebsiella strains isolated in Zagreb hospitals were ESBL
producers [35]. At the SUH, the prevalence of ESBL produc-
ers varied considerably between different wards (Table 2). Our
results concerning the high prevalence of ESBL-producing
isolates in neonatal and adult ICUs are largely in accordance
with published data from other countries [2,12,17,19].
β-LACTAMASES-PRODUCING BACTERIA
Table 2. Frequency of ESBL-producing Escherichia coli and Klebsiella
pneumoniae isolates in the different hospital settings
Number of ESBL-producing isolates
E. coli K. pneumoniae Total
Tested/resistant Tested/resistant Tested/resistant
(%) (%) (%)
Pediatric patients 773/118 (15.3) 187/120 (64.2) 960/238 (24.8
Neonatal ICU 175/49 (28) 68/52 (76.5) 243/101 (41.6)
Pediatric ward 598/69 (11.5) 119/ 68 (57.1) 717/137 (19.1)
p < 0.0001* p = 0.013* p < 0.0001*
Adult patients 2957/58 (1.9) 528/143 (27.1) 3485/201 (5.8)
ICU 39/3 (7.7) 41/12 (29.3) 80/15 (18.7)
Other wardsa 2918/55 (1.9) 487/131 (26.9) 3405/186 (5.5)
P < 0.0001* P = 0.96 P < 0.0001*
a Medicine, obstetric/gynecology, neurology, neurosurgery, surgery, urology, orthope-
dics, oncology, infectious diseases, etc.
* Significant.
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Organisms producing ESBL are typically multidrug-
resistant [6,9,16,37]. A patient’s previous exposure to an
antibiotic, especially to extended-spectrum cephalosporins,
has been widely reported as a risk factor for infection with
ESBL-producing bacteria [30–32]. The high prevalence of
ESBL-producing isolates described in this study was proba-
bly due to the large amount of third-generation cephalosporins
consumed by SUH patients, especially those in the pediatric
ward. Although the consumption of third-generation
cephalosporins increased throughout the study period, the
prevalence of ESBL producers isolated from the SUH
remained almost the same, which suggests that ESBL-pro-
ducing strains are already endemic in the hospital.
Compared with ESBL-negative isolates, ESBL-positive
K. pneumoniae isolates were more often resistant to aminogli-
cosydes, ciprofloxacin, and cotrimoxazole. This association
between ESBL production and decreased susceptibility to non-
β-lactams is in line with the findings of previous investigations
[8,32,33]. The lower resistance to ciprofloxacin and cotrimox-
azole of ESBL-positive E. coli isolates than ESBL-negative
isolates (Table 3) is in contrast to the results of other reports
[25,27,36], in which higher resistance was usually found in
ESBL-positive E. coli isolates. The explanation for this differ-
ence may be that, in other studies, most ESBL-negative E. coli
isolates originated from adult patients treated with fluoro-
quinolones (norfloxacin or ciprofloxacin) or cotrimoxazole for
urinary-tract infections. Since most ESBL-producing E. coli
isolates in our hospital originated from neonates and pediatric
patients, the conflicting results possibly reflect the difference
in the prescription patterns of cotrimoxazole and ciprofloxacin
with respect to patient age.
In our study, the resistance of ESBL-producers to non-β-
lactam antibiotics differed considerably between isolates from
pediatric and adult patients. Most ESBL-positive strains were
resistant to aminoglycosides, in particular to gentamicin.
Resistance of E. coli and K. pneumoniae to ciprofloxacin was
found only in isolates obtained from adult patients. These data
probably reflect more frequent treatment of adult patients with
fluoroquinolones, since a major factor in ciprofloxacin resist-
ance is the consumption of fluoroquinolones [27,28]. Pediatric
ESBL-positive isolates were less resistant to cotrimoxazole
than isolates from adults, which might be due to prescription
patterns, since fluoroquinolones are not administered to chil-
dren. In contrast to the results of our study, Oteo et al. [25]
reported non-significant differences in the resistance of ESBL-
positive E. coli to fluoroquinolones between isolates from chil-
dren and those from adults. They also reported higher resist-
ance to cotrimoxazole in children than in adults.
During the entire study period, all ESBL-positive isolates
were susceptible to carbapenems, indicating that they are the
drugs of choice for treating serious infections caused by
ESBL-producing microorganisms [26].
In conclusion, the results of this study also suggest the
importance of ESBL-producing Enterobacteriaceae as a
cause of infections at the SUH. The high prevalence of mul-
tidrug-resistant organisms should be taken into account when
choosing therapeutic agents, especially for pediatric patients.
Since resistance can differ according to geographic location,
continuous local monitoring of resistance patterns is neces-
sary to adequately select an empirical antimicrobial therapy.
Further studies aimed at unraveling the molecular mecha-
nisms of resistance will provide a better understanding of the
epidemiology associated with ESBL-producing species of
Enterobacteriaceae. 
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TONKIC ET AL.
Prevalencia y resistencia antimicrobiana 
de cepas de Escherichia coli y Klebsiella
pneumoniae productoras de β-lactamasas 
de espectro extendido aisladas en un
hospital universitario de Split (Croacia)
Resumen. Se ha investigado la frecuencia de Escherichia coli y Klebsiella
pneumoniae productoras de β-lactamasas de espectro extendido (ESBL) en
pacientes de un hospital universitario de Split (Croacia). Los pacientes se
agruparon en relación con la edad, el tipo de antibiótico recetado y la ubicación
en el hospital. Desde enero de 2001 a diciembre de 2002 se realizaron ensayos
de susceptibilidad a antimicrobianos en aislados de E. coli y K. pneumoniae. La
producción de ESBL fue ensayada mediante tests de sinergia de disco doble. En
todos los lugares de infección se detectaron aislados de E. coli y K. pneumoniae
productores de ESBL. En las salas de pediatría se detectaron los porcentajes
más elevados de ESBL-positivos. Los antibióticos más recetados en el hospital
fueron las cefalosporinas de tercera generación. Entre los aislados productores
de ESBL, los de E. coli fueron más resistentes a los aminoglicósidos, pero
menos a ciprofloxacina y cotrimoxazol. Sólo se halló resistencia de E. coli y
K. pneumoniae a la ciprofloxacina en aislados obtenidos de pacientes adultos.
Ningún aislado, independientemente de la producción de ESBL, fue resistente
a los carbapenemos. Se hallaron diferencias en la incidencia y resistencia
antimicrobiana de los aislados de E. coli y K. pneumoniae productores de
ESBL entre pacientes pediátricos y pacientes adultos. [Int Microbiol 2005;
8(2):119-124]
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Prevalência e resistência antimicrobiana 
de cepas de Escherichia coli e Klebsiella
pneumoniae produtoras de β-lactamases 
de largo espetro isoladas em um hospital
universitário de Split (Croácia)
Resumo. A freqüência de Escherichia coli e Klebsiella pneumoniae
produtoras de β-lactamasas de amplo espectro (ESBL) foi investigada em
pacientes de um hospital universitário de Split (Croácia), em relação com a
idade, o grupo de antibiótico receitado e a localização. Desde janeiro de
2001 a dezembro de 2002 foram realizados ensaios de suscetibilidade a
diferentes antimicrobianos em isolados de E. coli e K. pneumoniae. A
produção de ESBL foi ensaiada mediante testes de sinergia de disco duplo.
Em todos os lugares de infecção foram detectados isolados de E. coli e K.
pneumoniae produtores de ESBL. Nas salas de pediatria foram detectados os
valores mais elevados de ESBL. Os antibióticos mais prescritos no hospital
foram as cefalosporinas de terceira geração. Entre os isolados produtores de
ESBL, os de E. coli foram mais resistentes aos aminoglicósidos, mas menos
a ciprofloxacina e co-trimoxazol. Só foi achada resistência de E. coli e K.
pneumoniae à ciprofloxacina em isolados obtidos de pacientes adultos.
Nenhum isolado, independentemente da produção de ESBL, foi resistente
aos carbapenemos. Foram encontradas diferenças na incidência e resistência
antimicrobiana dos isolados de E. coli e K. pneumoniae produtores de ESBL
entre pacientes pediátricos e pacientes adultos. [Int Microbiol 2005;
8(2):119-124]
Palavras chave: Escherichia coli · Klebsiella pneumoniae · resistència
a antibióticos · β-lactamase de largo espetro (ESBL)
